Katie Tryhane
Stock Analyst at Credit Suisse
(2.03)
# 2,781
Out of 4,825 analysts
21
Total ratings
50%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Katie Tryhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Initiates: Outperform | $285 | $116.89 | +143.82% | 1 | Aug 25, 2022 | |
| AVTR Avantor | Maintains: Outperform | $47 → $50 | $12.99 | +285.06% | 1 | Sep 10, 2021 | |
| DHR Danaher | Maintains: Outperform | $306 → $370 | $196.86 | +87.95% | 1 | Sep 10, 2021 | |
| SOPH SOPHiA GENETICS | Initiates: Outperform | $22 | $3.01 | +630.90% | 1 | Aug 17, 2021 | |
| IDXX IDEXX Laboratories | Maintains: Outperform | $735 → $770 | $471.38 | +63.35% | 2 | Aug 13, 2021 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Outperform | $44 → $54 | $2.04 | +2,553.56% | 3 | Aug 11, 2021 | |
| FLGT Fulgent Genetics | Maintains: Underperform | $55 → $65 | $17.26 | +276.59% | 2 | Aug 10, 2021 | |
| ZTS Zoetis | Maintains: Outperform | $206 → $230 | $155.65 | +47.77% | 2 | Aug 9, 2021 | |
| NVST Envista Holdings | Maintains: Outperform | $49 → $55 | $16.37 | +236.08% | 2 | May 6, 2021 | |
| LNTH Lantheus Holdings | Maintains: Neutral | $17 → $20 | $105.92 | -81.12% | 1 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $488 → $490 | $419.89 | +16.70% | 2 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $432 → $515 | $176.74 | +191.39% | 2 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $235 | $145.21 | +61.83% | 1 | Oct 22, 2020 |
Charles River Laboratories International
Aug 25, 2022
Initiates: Outperform
Price Target: $285
Current: $116.89
Upside: +143.82%
Avantor
Sep 10, 2021
Maintains: Outperform
Price Target: $47 → $50
Current: $12.99
Upside: +285.06%
Danaher
Sep 10, 2021
Maintains: Outperform
Price Target: $306 → $370
Current: $196.86
Upside: +87.95%
SOPHiA GENETICS
Aug 17, 2021
Initiates: Outperform
Price Target: $22
Current: $3.01
Upside: +630.90%
IDEXX Laboratories
Aug 13, 2021
Maintains: Outperform
Price Target: $735 → $770
Current: $471.38
Upside: +63.35%
Maravai LifeSciences Holdings
Aug 11, 2021
Maintains: Outperform
Price Target: $44 → $54
Current: $2.04
Upside: +2,553.56%
Fulgent Genetics
Aug 10, 2021
Maintains: Underperform
Price Target: $55 → $65
Current: $17.26
Upside: +276.59%
Zoetis
Aug 9, 2021
Maintains: Outperform
Price Target: $206 → $230
Current: $155.65
Upside: +47.77%
Envista Holdings
May 6, 2021
Maintains: Outperform
Price Target: $49 → $55
Current: $16.37
Upside: +236.08%
Lantheus Holdings
May 5, 2021
Maintains: Neutral
Price Target: $17 → $20
Current: $105.92
Upside: -81.12%
Dec 2, 2020
Maintains: Neutral
Price Target: $488 → $490
Current: $419.89
Upside: +16.70%
Nov 24, 2020
Maintains: Outperform
Price Target: $432 → $515
Current: $176.74
Upside: +191.39%
Oct 22, 2020
Maintains: Outperform
Price Target: $230 → $235
Current: $145.21
Upside: +61.83%